First European Conference on SRS/SBRT and IG-IMRT Held in Milan
SUNNYVALE, Calif., March 4, 2013– Accuray Incorporated (Nasdaq: ARAY), today announced highlights from the First European Conference on stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) and image-guided intensity-modulated radiation therapy (IG-IMRT), hosted in partnership with the Istituto Europeo di Oncologia Milano and the Università degli studi di Milano, held in Milan, Italy on February 22-23, 2013.
The conference “Radiation Oncology: can we still treat without image guidance?” was attended by more than 400 healthcare professionals, including radiation oncologists, medical physicists and hospital administrators from 32 countries. Outcomes of recent research in areas such as central nervous system (CNS), head and neck, breast, lung, gastrointestinal (GI), pelvis, total marrow irradiation (TMI) and pediatrics were presented.
The independent Scientific Committee, led by Prof. Roberto Orecchia (Istituto Europeo di Oncologia Milano, Italy) and Prof. Eric Lartigau (Centre Oscar Lambret, Lille, France), focused on new developments in the field and developed an educational event to discuss the need of image guidance for a variety of clinical indications in modern radiation therapy. “Daily image guidance is crucial for all high-precision treatments, also for palliative treatments” said Prof. Eric Lartigau.
“The TomoTherapy® System provides an automatic process that makes our daily work easy” said Prof. Dirk Verellen, UZ Brussel.
Prof. Ben Heijmen, Erasmus MC-Daniel den Hoed Cancer Center of Rotterdam, said “Additionally, dose to the healthy tissue can be strongly reduced using optimal and numerous non-coplanar beams when treating prostate cancer” comparing non-coplanar treatments to coplanar treatments.
“There are non-adaptive and real-time adaptive solutions, but the only solution that adapts for target motion in real-time, available clinically, is the CyberKnife® System”, added Dr. Iciar Santa Olalla.
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, and the Company’s leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading “Risk Factors” in the company’s report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Qs filed on November 8, 2012 & February 6, 2013, and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.